communication after announcerT from FDA Breakthrough Device Designation for the Prima system in dry AMD

• Conversion of 160 ORNAN2022 by ESGO intending to engage in controlled trading of shares
• Implemented cost reduction measures potentially extending cash runway beyond the end of Q2 2023
• Continuing the fundraising process
• Breakthrough device designation status to streamline FDA’s regulatory review process

Paris, April 3, 2023 – 7:00 CET – Pixium Vision SA (Euronext Growth Paris – FR0011950641; Mnemonic: ALPIX), a bioelectronics company developing innovative bionic vision systems to help patients who have lost their sight to live more independently, welcomes the interest of the market updates on its business following the announcement of FDA Breakthrough Device Designation for the Prima system in dry AMD and reports that the European Select Growth Opportunities Fund (“ESGO”), the US healthcare-focused investor, converted ORNAN2022. On Friday March 31, 2023, ESGO converted 160 ORNAN2022 for a total consideration of EUR 1,600,000 and the issuance of a total of 65,573,769 common shares, making ESGO a major shareholder of Pixium Vision.¹ The conversion took place due to the increased interest in Pixium Vision shares after that of the company announcement of Reception the FDA Breakthrough Device Designation for the Prima system with dry AMD on Friday, March 31, 2023. This appreciation supports the market’s continued interest in the PRIMA technology and the development of its clinical trials and regulatory process in the United States. After this conversion, the company’s share capital amounts to EUR 2,980,403.72, represented by 148,664,926 shares.

“We welcome the increased interest at Pixium Vision the following one more thAn 300% increase in our share price on Friday last week. Hsave receive Bbreakthrough DDevice DWithdrawing from the FDA in the US is truly a remarkable…